These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

687 related articles for article (PubMed ID: 28117224)

  • 1. Drug resistance mechanisms and novel drug targets for tuberculosis therapy.
    Islam MM; Hameed HMA; Mugweru J; Chhotaray C; Wang C; Tan Y; Liu J; Li X; Tan S; Ojima I; Yew WW; Nuermberger E; Lamichhane G; Zhang T
    J Genet Genomics; 2017 Jan; 44(1):21-37. PubMed ID: 28117224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis: classical and new drugs.
    Almeida Da Silva PE; Palomino JC
    J Antimicrob Chemother; 2011 Jul; 66(7):1417-30. PubMed ID: 21558086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Frontier of mycobacterium research--host vs. mycobacterium].
    Okada M; Shirakawa T
    Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug targets exploited in Mycobacterium tuberculosis: Pitfalls and promises on the horizon.
    Bhat ZS; Rather MA; Maqbool M; Ahmad Z
    Biomed Pharmacother; 2018 Jul; 103():1733-1747. PubMed ID: 29864964
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of drug resistance in Mycobacterium tuberculosis: update 2015.
    Zhang Y; Yew WW
    Int J Tuberc Lung Dis; 2015 Nov; 19(11):1276-89. PubMed ID: 26467578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mycobacterium tuberculosis cytochrome P450 enzymes: a cohort of novel TB drug targets.
    Hudson SA; McLean KJ; Munro AW; Abell C
    Biochem Soc Trans; 2012 Jun; 40(3):573-9. PubMed ID: 22616869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Drug resistance in Mycobacterium tuberculosis: contribution of constituent and acquired mechanisms].
    Gómez-Tangarife VJ; Gómez-Restrepo AJ; Robledo-Restrepo J; Hernández-Sarmiento JM
    Rev Salud Publica (Bogota); 2018; 20(4):491-497. PubMed ID: 30843986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advancements in the development of anti-tuberculosis drugs.
    Chetty S; Ramesh M; Singh-Pillay A; Soliman ME
    Bioorg Med Chem Lett; 2017 Feb; 27(3):370-386. PubMed ID: 28017531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targets in M. tuberculosis: search for new drugs.
    Lamichhane G
    Trends Mol Med; 2011 Jan; 17(1):25-33. PubMed ID: 21071272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole genome sequencing of Mycobacterium tuberculosis for detection of drug resistance: a systematic review.
    Papaventsis D; Casali N; Kontsevaya I; Drobniewski F; Cirillo DM; Nikolayevskyy V
    Clin Microbiol Infect; 2017 Feb; 23(2):61-68. PubMed ID: 27665704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Priming the tuberculosis drug pipeline: new antimycobacterial targets and agents.
    Evans JC; Mizrahi V
    Curr Opin Microbiol; 2018 Oct; 45():39-46. PubMed ID: 29482115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and future trends in the diagnosis and treatment of drug-susceptible and multidrug-resistant tuberculosis.
    Ahmad S; Mokaddas E
    J Infect Public Health; 2014; 7(2):75-91. PubMed ID: 24216518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent developments in genomics, bioinformatics and drug discovery to combat emerging drug-resistant tuberculosis.
    Swaminathan S; Sundaramurthi JC; Palaniappan AN; Narayanan S
    Tuberculosis (Edinb); 2016 Dec; 101():31-40. PubMed ID: 27865394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapeutic targets in tuberculosis: post-genomic era.
    Khasnobis S; Escuyer VE; Chatterjee D
    Expert Opin Ther Targets; 2002 Feb; 6(1):21-40. PubMed ID: 11901479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of epigenetics, bacterial and host factors in progression of Mycobacterium tuberculosis infection.
    Marimani M; Ahmad A; Duse A
    Tuberculosis (Edinb); 2018 Dec; 113():200-214. PubMed ID: 30514504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamins Based Novel Target Pathways/Molecules as Possible Emerging Drug Targets for the Management of Tuberculosis.
    Sharma A; Jain K; Flora SJS
    Med Chem; 2018; 14(3):212-224. PubMed ID: 29110620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug targets in dormant Mycobacterium tuberculosis: can the conquest against tuberculosis become a reality?
    Gupta VK; Kumar MM; Singh D; Bisht D; Sharma S
    Infect Dis (Lond); 2018 Feb; 50(2):81-94. PubMed ID: 28933243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs.
    Liu Y; Wang BX; Liu ZY; Han Y; Tan YJ; Li XJ; Liu JX; Tan S; Zhang TY
    Yi Chuan; 2016 Oct; 38(10):928-939. PubMed ID: 27806934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular identification of mutations associated with anti-tuberculosis drug resistance among strains of Mycobacterium tuberculosis.
    Abbadi SH; Sameaa GA; Morlock G; Cooksey RC
    Int J Infect Dis; 2009 Nov; 13(6):673-8. PubMed ID: 19138546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.